Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...
Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.
Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...
Cancer survival is improving, but what about life after treatment? Doctors explain the hidden reproductive and hormonal impact of chemotherapy.
LexBio and Hiteck partner to develop novel drug candidates using AI-driven molecular glue degraders targeting B- and ...
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...
Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three doses of STAR-LLD administered by continuous ...
After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.
A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...
CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.
Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results